ARCHIVES

Gleevec Improves Survival Of CML In Accelerated Phase

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

“Whatever Happened To…?” ACS Follows Up Five Years Later

August 26, 1977

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004

Ungerleider To Leave NCI For Theradex Corp.

November 24, 2000

Text of Peer Review Of Medenica’s Treatment Of Breast Cancer Patient

April 30, 1993

NRC considering “Escalated” Enforcement Action Against NIH

February 2, 1996